Zhipu (02513.HK) is reportedly considering a Hong Kong share placement to raise several billion U.S. dollars, potentially as early as next month.

WuXi Biologics said its MFG17 biologics drug-substance plant at the Shanghai Fengxian campus completed its first GMP production. MFG17 is the company’s 25th global drug-substance facility and will provide scaled clinical and commercial supply for multiple biologics. The plant is equipped with multiple single-use bioreactors (SUBs), has 9,000‑liter capacity and is designed for about 80–100 drug-substance batches a year.

Bank of England policymaker Taylor said the Bank's structural bias toward asset sales under quantitative tightening (QT), as in 2025, will remain a consideration in policy decisions this year.